secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cytosorbents Corp (CTSO)
CIK:        0001175151
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0000929638-25-004243
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud

CytoSorbents Reports Q3 2025 Revenue of $9.5M, Up 10% YoY, and Provides Business Update
--------------------------------------------------------------------------------

- Revenue was $9.5 million for Q3 2025, a 10% increase from $8.6 million in Q3 2024, driven by record distributor sales.
- Amended credit agreement with Avenue Capital Group added $2.5 million in term loans and extended interest-only period to December 31, 2026.
- Workforce reduction of approximately 10% implemented to accelerate path to cash-flow breakeven by Q1 2026, with up to $900,000 in restructuring charges.
- Pre-submission meeting request for DrugSorb-ATR De Novo application submitted to FDA; formal submission expected Q1 2026 with regulatory decision anticipated mid-2026.
- Gross margin improved to 70% from 61% a year ago; operating loss narrowed to $2.9 million from $4.8 million.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1175151/000092963825004243/0000929638-25-004243-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1175151/000092963825004243/a8k.htm
  HTML page:      https://secwatch.observer/filing/0000929638-25-004243

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer